Of four treatment response measures recorded at 6 months of mepolizumab treatment, an Asthma Control Questionnaire score was ...

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- A set of chameleon-like immune cells could be contributing to severe asthma in ...

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted ...

Exhaled Nitric Oxide and Sputum Eosinophils are Complementary Tools for Diagnosing Occupational Asthma suggests a study published in the Allergy.Exposure-related changes in exhaled nitric ...

If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...